Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program

Two randomized, double‐blind, placebo‐controlled studies demonstrated responses (≥50 000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The long‐term safety and efficacy of fostamatinib were evaluated in a follow‐on, open‐label extension (OLE) study. Patients receive...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Hematol
Hlavní autoři: Bussel, James B., Arnold, Donald M., Boxer, Michael A., Cooper, Nichola, Mayer, Jiri, Zayed, Hany, Tong, Sandra, Duliege, Anne‐Marie
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594140/
https://ncbi.nlm.nih.gov/pubmed/30784097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25444
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky